Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Short-term Investments (2016 - 2025)

Regenxbio (RGNX) has 11 years of Short-term Investments data on record, last reported at $195.6 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 10.41% year-over-year to $195.6 million; the TTM value through Dec 2025 reached $195.6 million, up 10.41%, while the annual FY2025 figure was $195.6 million, 10.41% up from the prior year.
  • Short-term Investments reached $195.6 million in Q4 2025 per RGNX's latest filing, down from $215.4 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $281.6 million in Q2 2022 and bottomed at $111.5 million in Q3 2021.
  • Average Short-term Investments over 5 years is $206.8 million, with a median of $220.6 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: soared 139.31% in 2022, then crashed 38.97% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $112.2 million in 2021, then surged by 138.52% to $267.7 million in 2022, then fell by 10.07% to $240.7 million in 2023, then fell by 26.41% to $177.2 million in 2024, then rose by 10.41% to $195.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $195.6 million in Q4 2025, $215.4 million in Q3 2025, and $243.7 million in Q2 2025.